“The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence,”

Meg Doherty · said date not stated · reported 2025-07-14

The WHO issued recommendations regarding the use of injectable lenacapavir for HIV prevention.